Get the Stockscreener App
91.25
1.78%
-1.65
After Hours:
91.25
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $91.25, with a volume of 1.33M.
It is down -1.78% in the last 24 hours and down -9.96% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$92.90
Open:
$93.01
24h Volume:
1.33M
Relative Volume:
1.15
Market Cap:
$11.29B
Revenue:
$2.72B
Net Income/Loss:
$254.30M
P/E Ratio:
44.16
EPS:
2.0665
Net Cash Flow:
$564.37M
1W Performance:
-2.92%
1M Performance:
-9.96%
6M Performance:
-25.49%
1Y Performance:
-12.55%
1-Day Range:
$91.19
$93.25
1-Week Range:
$89.39
$94.70
52-Week Range:
$88.53
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
91.25 | 11.29B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
UBS Upgrades Revvity (BMV:RVTY) - Nasdaq
UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq
UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia
UBS Upgrades Revvity (LSE:0KHE) - Nasdaq
UBS Upgrades Revvity (RVTY) - Nasdaq
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus
UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | RVTY Stock News - GuruFocus
Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus
KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com
Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan
Revvity to Present at Upcoming Investor Conferences - Business Wire
Revvity Reports Strong Q1 2025 Financial Results - TipRanks
Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN
Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada
Biotech Firm Revvity Reports Better-Than-Expected Earnings - MSN
Stifel maintains Revvity stock Hold rating, $120 target - Investing.com
Revvity (RVTY) Price Target Adjusted by Baird After Q1 Results | - GuruFocus
Revvity, Inc. (NYSE:RVTY) Q1 2025 Earnings Call Transcript - Insider Monkey
Revvity Exceeds Expectations: Strong Biotech Demand Fuels GrowthNews and Statistics - IndexBox
Revvity First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Raymond James Adjusts Price Target on Revvity to $120 From $145, Maintains Outperform Rating - marketscreener.com
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... - Yahoo Finance
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... By GuruFocus - Investing.com Canada
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing - GuruFocus
Jefferies Updates Revvity (RVTY) Price Target Amid Market Develo - GuruFocus
Revvity’s Earnings Call: Balanced Growth Amid Challenges - TipRanks
Revvity (RVTY) Price Target Reduced by Citi to $135, Buy Rating Maintained | RVTY Stock News - GuruFocus
Jefferies Cuts Price Target on Revvity to $106 From $130 - marketscreener.com
Earnings call transcript: Revvity beats Q1 2025 earnings expectations - Investing.com
Earnings call transcript: Revvity beats Q1 2025 earnings expectations By Investing.com - Investing.com India
Revvity: Q1 Earnings Snapshot - The Wilton Bulletin
Revvity (RVTY) Exceeds Q1 Expectations with Robust Diagnostics G - GuruFocus
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up - Nasdaq
Revvity Q1 2025 slides: 4% organic growth driven by strong Diagnostics performance - Investing.com
Evercore ISI Adjusts Price Target on Revvity to $116 From $125 - marketscreener.com
Revvity's Steady Demand Lifts Q1 Results Above Expectations - Finimize
Earnings Summary: Revvity (RVTY) reports higher revenue and earnings for Q1 2025 - AlphaStreet
Revvity Q1 Earnings Surpass Street Estimates, Investors Cheer 2025 Revised Revenue Guidance - MSN
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
Revvity (RVTY) Surpasses Q1 Estimates and Updates 2025 Outlook - GuruFocus
Revvity, Inc. (RVTY) Implements Majority Voting Standard Followi - GuruFocus
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):